Cadila Pharmaceuticals launches Tikacad an anti-platelet drug-containing Ticagrelor for coronary artery disease therapeutics market
The rising prevalence of coronary artery disease is a prime factor driving the growth of the coronary artery disease therapeutics market. According to the World Health Organization, cardiovascular diseases (CVDs) are the leading cause of death globally. An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke. Out of the 17 million premature deaths (under the age of 70) due to noncommunicable diseases in 2019, 38% were caused by CVDs. High blood pressure, diabetes or insulin resistance, high cholesterol, sedentary lifestyle, and hypertension are some of the factors that caused coronary artery disease. In October 2020, Cadila Pharmaceuticals launches Tikacad in India, an anti-platelet drug-containing Ticagrelor, a P2Y12 platelet inhibitor indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with the acute coronary syndrome (ACS) In June...